摘要 |
HIV replication inhibitors of formula (I), N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof, wherein -a<SUP>1</SUP>=a<SUP>2</SUP>-a<SUP>3</SUP>=a<SUP>4</SUP>- is -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N-, -N=N-CH=CH-; -b<SUP>1</SUP>=b<SUP>2</SUP>-b<SUP>3</SUP>=b<SUP>4</SUP>- is -CH=CH-CH=CH-, -N=CH-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N-, -N=N-CH=CH-; R<SUP>1</SUP> is hydrogen; aryl; formyl; C<SUB>1-6</SUB>alkylcarbonyl; optionally substituted C<SUB>1-6</SUB>alkyl; C<SUB>1-6</SUB>alkyloxycarbonyl; R<SUP>2</SUP> is OH; halo; optionally substituted C<SUB>1-6</SUB>alkyl, C<SUB>2-6</SUB>alkenyl or C<SUB>2-6</SUB>alkynyl; substituted carbonyl; carboxyl; CN; nitro; amino; substituted amino; polyhalomethyl; polyhalomethylthio; -S(=O)<SUB>P</SUB>R<SUP>6</SUP>; C(=NH)R<SUP>6</SUP>; R<SUP>2a</SUP> is CN; amino; substituted amino; optionally substituted C1-6alkyl; halo; optionally substituted C<SUB>1-6</SUB>alkyloxy; substituted carbonyl; -CH=N-NH-C(O)-R<SUP>16</SUP>; optionally substituted C<SUB>1-6</SUB>alkyloxyC<SUB>1-6</SUB>alkyl; substituted C<SUB>2-6</SUB>alkenyl or C<SUB> 2-6</SUB> alkynyl; -C(=N-O-R<SUP>8</SUP>)-C<SUB>1-4</SUB>alkyl; R<SUP>7</SUP> or -X<SUB>3</SUB>-R<SUP>7</SUP>; X<SUB>1</SUB> is -NR<SUP>1</SUP>-, -O-, -C(=O)-, -CH<SUB>2</SUB>-, -CHOH-, -S-, -S(=O)<SUB>P</SUB>- R<SUP>3</SUP> is CN; amino; C<SUB>1-6</SUB>alkyl; halo; optionally substituted C<SUB>1-6</SUB>alkyloxy; substituted carbonyl; -CH=N-NH-C(O)-R<SUP>16</SUP>; substituted C<SUB>1-6</SUB>alkyl; optionally substituted C<SUB>1-6</SUB>alkyloxyC<SUB>1-6</SUB>alkyl; substituted C<SUB>2-6</SUB>alkenyl or C<SUB>2-6</SUB>alkynyl; -C(=N-O-R<SUP>8</SUP>)-C<SUB>1-4</SUB>alkyl; R<SUP>7</SUP>; -X<SUB>3</SUB>-R<SUP>7</SUP> ; R<SUP>4</SUP> is halo; OH; optionally substituted C<SUB>1-6</SUB>alkyl, C<SUB>2-6</SUB>alkenyl or C<SUB>2-6</SUB>alkynyl; C<SUB>3-7</SUB>cycloalkyl; C<SUB>1-6</SUB>alkyloxy; CN; nitro; polyhaloC<SUB>1-6</SUB>alkyl; polyhaloC<SUB>1-6</SUB>alkyloxy; substituted carbonyl; formyl; amino; mono- or di(C<SUB>1-4</SUB>alkyl)amino or R<SUP>7</SUP>; R<SUP>5</SUP> is a 5- or 6-membered completely unsaturated ring system wherein 1 - 4 ring members are nitrogen, oxygen or sulfur; which ring may optionally be substituted and may optionally be annelated with a benzene ring; methods for their preparation and pharmaceutical compositions comprising them. The invention also relates to the use of these compounds for the prevention or the treatment of HIV infection. |
申请人 |
TIBOTEC PHARMACEUTICALS LTD.;GUILLEMONT, JEROME, EMILE, GEORGES;HEERES, JAN;LEWI, PAULUS, JOANNES |
发明人 |
GUILLEMONT, JEROME, EMILE, GEORGES;HEERES, JAN;LEWI, PAULUS, JOANNES |